<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19539" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Chronic Kidney Transplant Rejection</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hassanein</surname>
            <given-names>Mohamed</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Augustine</surname>
            <given-names>Joshua J.</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohamed Hassanein declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joshua Augustine declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19539.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Kidney transplantation is currently the definitive treatment for patients with end-stage kidney disease (ESKD). Compared to dialysis, kidney transplantation is associated with reduced mortality and improved quality of life. Rejection of the kidney is one of the leading causes of allograft loss. This activity reviews the epidemiology, etiology, classification, diagnosis, and management of chronic kidney transplant rejection and highlights the role of the interprofessional team in the care of patients with this condition. It specifically focuses on the immune mechanisms of chronic kidney transplant rejection, the characteristic histopathological lesions of immune-mediated chronic rejection, how to differentiate chronic rejection from other causes of renal allograft dysfunction, and how to effectively diagnose and manage patients with chronic rejection.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology and classification of chronic kidney transplant rejection.</p></list-item><list-item><p>Describe the characteristic histopathological lesions of chronic active antibody-mediated and t cell-mediated rejection.</p></list-item><list-item><p>Review the current diagnostic approach to a patient with suspected chronic kidney transplant rejection.</p></list-item><list-item><p>Explain the role of the interprofessional team is the prevention and management of chronic kidney transplant rejection.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19539&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19539">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19539.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Kidney transplantation is currently the definitive treatment for patients with end-stage kidney disease (ESKD). Compared to dialysis, kidney transplantation is associated with reduced mortality and improved quality of life.<xref ref-type="bibr" rid="article-19539.r1">[1]</xref>&#x000a0;Rejection of the kidney is one of the leading causes of allograft loss. Other causes of kidney allograft loss include recurrent glomerular disease, fibrosis, calcineurin-inhibitor (CNI) toxicity, and BK virus-associated nephropathy.<xref ref-type="bibr" rid="article-19539.r2">[2]</xref><xref ref-type="bibr" rid="article-19539.r3">[3]</xref>&#x000a0;Kidney allograft rejection can subdivide into hyperacute, accelerated, acute, and chronic rejection.<xref ref-type="bibr" rid="article-19539.r4">[4]</xref>&#x000a0;Chronic kidney transplant rejection (CKTR) refers to graft failure and rejection beyond 1-year post-transplant, in the absence of acute rejection, drug toxicity (particularly CNIs), and other causes of nephropathy. Chronic kidney injury after transplantation was previously often labeled as &#x0201c;chronic allograft nephropathy,&#x0201d; a term that has fallen out of favor, replaced by biopsy-specific findings that may point to chronic immune injury or display interstitial fibrosis and tubular atrophy (IFTA) which are non-specific findings.<xref ref-type="bibr" rid="article-19539.r5">[5]</xref><xref ref-type="bibr" rid="article-19539.r6">[6]</xref></p>
      </sec>
      <sec id="article-19539.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>CKTR can be due to cell-mediated or humoral immune response and usually occurs in patients with insufficient immunosuppression or medication nonadherence.<xref ref-type="bibr" rid="article-19539.r7">[7]</xref>&#x000a0;Acute rejection (AR) is one of the risk factors for late kidney allograft loss. El Ters et al. studied the effect of AR on graft histology in a cohort of 797 renal transplant patients without donor-specific antibodies (DSA) during the time of transplant. AR was the etiology in 15.2% of patients. One and 2-year biopsies of patients with a history of AR were associated with more inflammation, fibrosis, transplant glomerulopathy (TG), and early allograft loss.<xref ref-type="bibr" rid="article-19539.r8">[8]</xref>&#x000a0;Lorentz et al. further studied the effect of immunosuppression nonadherence on graft histology. Non-adherence with immunosuppressive therapy at five years post-transplant was associated with increased fibrosis and inflammation but not TG.<xref ref-type="bibr" rid="article-19539.r9">[9]</xref></p>
        <p>Non-immune risk factors for late allograft loss include delayed graft function, immunosuppressive medication toxicity, recurrence of primary kidney disease, diabetes, hypertension, and hyperlipidemia.<xref ref-type="bibr" rid="article-19539.r10">[10]</xref><xref ref-type="bibr" rid="article-19539.r11">[11]</xref>&#x000a0;These factors can potentiate the normal aging process of transplanted kidneys, exacerbating chronic injury, and further contributing to graft loss.</p>
      </sec>
      <sec id="article-19539.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Alloimmunity is one of the most frequent causes of graft loss. Nankivell et al. reported a 25.8% incidence of subclinical rejection at 1-year post-transplant.<xref ref-type="bibr" rid="article-19539.r12">[12]</xref>&#x000a0;The Deterioration of Kidney Allograft Function Study (DeKAF) group biopsied 173 subjects (7.3 +/- 6.0 years post-transplant). Subjects who were positive for DSA, complement component C4d deposition on biopsy (discussed later), or both had an increased risk of kidney allograft failure two years post-transplant.<xref ref-type="bibr" rid="article-19539.r13">[13]</xref>&#x000a0;Sellares et al. studied the causes of allograft loss in 60 patients with failure out of a total cohort of 315 patients.<xref ref-type="bibr" rid="article-19539.r2">[2]</xref>&#x000a0;The incidence of antibody-mediated rejection increased over time in those with failure, especially after five years post-transplantation. Protocol biopsies by Stegall et al. reported a prevalence of moderate-severe fibrosis in 13% and 17% of patients at one and 5-years post-transplant, respectively. Moreover, 23% of allografts who had a biopsy at one and 5-years post-transplant showed progression in fibrosis from mild to severe forms.<xref ref-type="bibr" rid="article-19539.r14">[14]</xref>&#x000a0;Only 5% of tacrolimus treated patients, however, showed evidence of TG, a lesion characteristic of chronic antibody-mediated rejection, suggesting that the use of tacrolimus may help to prevent CKTR.<xref ref-type="bibr" rid="article-19539.r14">[14]</xref></p>
      </sec>
      <sec id="article-19539.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>CKTR is, by definition, immune-mediated and generally divides into chronic active antibody-mediated rejection (CAAMR) and chronic active T cell-mediated rejection (CATMR).<xref ref-type="bibr" rid="article-19539.r7">[7]</xref> CAAMR occurs due to DSA against human leukocytic antigens (HLA) and non-HLA antigens. DSAs can damage the endothelium both directly and indirectly through complement-mediated activation and inflammatory cell recruitment. An extended alloreactive immune response over a prolonged period leads to microvascular remodeling of both the glomerular and peritubular capillaries, microvascular inflammation, and arterial intimal fibrous thickening. Complement activation, identified by C4d deposition in the peritubular capillaries, also contributes to microvascular inflammation. However, C4d positivity was eliminated as a requirement for the diagnosis of CAAMR after the emergence of C4d negative antibody-mediated kidney rejection.<xref ref-type="bibr" rid="article-19539.r6">[6]</xref><xref ref-type="bibr" rid="article-19539.r7">[7]</xref></p>
        <p>Cell-mediated injury can involve both the renal tubulointerstitial or arterial components. Antigen-presenting cells (APC) present donor antigens to T cells, which then cross the microcirculation of the donor's kidney and enter the interstitium. Several cytokines are then produced, including interferon-gamma (IFN-&#x003b3;) and transforming growth factor-beta (TGF-beta), triggering a cascade of inflammation leading to tubulitis, the hallmark feature of CATMR.<xref ref-type="bibr" rid="article-19539.r15">[15]</xref>&#x000a0;T cell-mediated injury can also involve the arteries, leading to arterial inflammation and intimal fibrosis.<xref ref-type="bibr" rid="article-19539.r6">[6]</xref>&#x000a0;Ultimately progressive IFTA may be a late consequence of CATMR.</p>
      </sec>
      <sec id="article-19539.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>At the histopathological level, CKTR affects all parts of the kidneys, including the arteries, interstitium, glomeruli, and tubules. CAAMR leads to microvascular remodeling in both the glomerular or peritubular capillaries. Glomerular microvascular remodeling leads to TG, which is characterized by double contouring of glomerular capillary walls. Other histopathological features of antibody-mediated injury include peritubular capillary basement membrane multilayering and arterial intimal fibrosis.<xref ref-type="bibr" rid="article-19539.r6">[6]</xref><xref ref-type="bibr" rid="article-19539.r7">[7]</xref></p>
        <p>CATMR involves mainly the renal interstitium and arteries, leading to tubulitis and chronic allograft arteriopathy, respectively. Tubular inflammation leads to IFTA. Chronic allograft arteriopathy manifests primarily as arterial intimal fibrosis. Since DSAs in CAAMR can stimulate fibrosis of the arterial intima, it is challenging to differentiate arteriopathy secondary to CAAMR and CATMR on the histological level.<xref ref-type="bibr" rid="article-19539.r6">[6]</xref><xref ref-type="bibr" rid="article-19539.r7">[7]</xref></p>
      </sec>
      <sec id="article-19539.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The diagnosis of CKTR starts with clinical evaluation through a thorough history taking and a comprehensive physical exam. Important items to ask for during history taking include medication nonadherence, recurrence of the original cause of nephropathy, previous transplantation, prior AR, and baseline HLA sensitization. Unexplained decreases in immunosuppression levels can also point towards nonadherence as a cause for CKTR.<xref ref-type="bibr" rid="article-19539.r16">[16]</xref>&#x000a0;Medication nonadherence can also be due to health insurance problems. It is, therefore, crucial to ask about insurance coverage of immunosuppression medications. Medication history is also essential, as many drugs can affect the metabolism of immunosuppression medications, decreasing or increasing blood levels leading to rejection and toxicity, respectively. Physical examination findings are usually nonspecific but may include hypertension, lower extremity edema, and/or fatigue. Symptoms of severe AR, such as fever or graft tenderness, are typically absent in CKTR. More progressive stages of rejection can manifest as signs of kidney failure and uremia, including oliguria, nausea, vomiting, a metallic taste, pericardial friction rub, and asterixis.</p>
      </sec>
      <sec id="article-19539.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Early diagnosis of CKTR is imperative for early and successful treatment. As discussed above, the diagnosis of CKTR starts with clinical evaluation. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend biweekly clinic visits 3&#x000a0;to 6 months post-transplant, monthly visits 7&#x000a0;to 12 months post-transplant, and every 2&#x000a0;to 3 months after that.<xref ref-type="bibr" rid="article-19539.r17">[17]</xref></p>
        <p>Laboratory tests can help differentiate different causes of allograft dysfunction. Kidney allograft function assessed by serum creatinine (Cr) and estimated glomerular filtration rate (eGFR) requires measurement at or before each visit. The eGFR is suggested to be a more accurate indicator and predictor of graft function and long-term graft loss, respectively.<xref ref-type="bibr" rid="article-19539.r18">[18]</xref><xref ref-type="bibr" rid="article-19539.r19">[19]</xref>&#x000a0;Iothalamate GFR and cystatin C can also be used to evaluate graft function, especially in situations where Cr may be inaccurate due to extremes of muscle mass. Proteinuria over 500 mg/day may be an early marker of chronic kidney allograft dysfunction.<xref ref-type="bibr" rid="article-19539.r20">[20]</xref></p>
        <p>DSA is typically measured in an HLA laboratory using flow cytometry and the single antigen bead technique. Positive DSA is a relatively good marker for CAAMR. A decrease or disappearance of DSA can be used to monitor response to treatment.<xref ref-type="bibr" rid="article-19539.r18">[18]</xref>&#x000a0;DSA, however, may not always correlate with tissue injury. In the Deterioration of Kidney Allograft Function (DeKAF) trial, C4d positive biopsies showed an equal risk of graft failure regardless of the presence or absence of DSA.<xref ref-type="bibr" rid="article-19539.r13">[13]</xref>&#x000a0;Denovo-DSA (dnDSA) forming after transplantation has been implicated as a major cause of chronic graft loss and can be detected before graft dysfunction ensues. Prospective monitoring for dnDSA can provide an opportunity for early treatment before the establishment of irreversible graft injury.<xref ref-type="bibr" rid="article-19539.r21">[21]</xref></p>
        <p>Doppler ultrasonography (US) is a non-invasive and relatively inexpensive tool to assess kidney allograft vasculature. Resistance indices over 0.8 at three months have links to deterioration in graft function.<xref ref-type="bibr" rid="article-19539.r22">[22]</xref>&#x000a0;Contrast-enhanced US (CES) can help detect a decrease in graft function before the resistance index increases.<xref ref-type="bibr" rid="article-19539.r23">[23]</xref>&#x000a0;CES uses gas microbubbles to determine vascular perfusion. After intravenous contrast application, a flush with an increased mechanical index leads to the detection of kidney perfusion through &#x0201c;burst imaging.&#x0201d; One analysis showed that allograft perfusion was related to serum creatinine levels. CES evaluation of blood flow was also more sensitive, specific, and accurate than determining blood flow through conventional indices.<xref ref-type="bibr" rid="article-19539.r23">[23]</xref></p>
        <p>A biopsy is imperative for diagnosing CKTR. Graft histology (as described previously) provides visual evidence of the underlying pathology of graft dysfunction. C4d complement fragment deposition in the peritubular capillaries is a marker for antibody-mediated tissue injury.<xref ref-type="bibr" rid="article-19539.r16">[16]</xref>&#x000a0;Although C4d complement fragment deposition can help diagnosis, the emergence of C4d negative antibody-mediated rejection led to the removal of C4d as a diagnostic criterion in the Banff Classification Criteria for CAAMR (described later).<xref ref-type="bibr" rid="article-19539.r24">[24]</xref>&#x000a0;Genetic analysis of biopsy tissue has also been suggested to aid the diagnosis of allograft rejection in conjunction with histology. Researchers have identified increased expression of genes primarily related to natural killer cells and microvascular inflammation in both antibody-mediated and T cell-mediated rejection. Immunostaining can help differentiate antibody and T cell-mediated rejection, with CD56 and CD68 positivity linked more to antibody-mediated rejection.<xref ref-type="bibr" rid="article-19539.r25">[25]</xref></p>
        <p>The Banff classification, originally founded in 1991 and later updated in 2007, 2009, 2013, and 2017 established specific criteria for the diagnosis of kidney allograft rejection.<xref ref-type="bibr" rid="article-19539.r6">[6]</xref>&#x000a0;Based on the 2017 revised Banff criteria, CAAMR and CATMR are diagnosed and classified as follows:</p>
        <p>I) CAAMR (all criteria must be present):</p>
        <p>1. Histological evidence of chronic tissue injury (one or more of the following):</p>
        <list list-type="bullet">
          <list-item>
            <p>Transplant glomerulopathy without evidence of thrombotic microangiopathy or glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Severe multilayering of the glomerular basement membrane on electron microscopy</p>
          </list-item>
          <list-item>
            <p>New-onset arterial intimal fibrosis</p>
          </list-item>
        </list>
        <p>2.Evidence of antibody interaction with vascular endothelium (one or more of the following):</p>
        <list list-type="bullet">
          <list-item>
            <p>Linear C4d deposition of peritubular capillaries</p>
          </list-item>
          <list-item>
            <p>Moderate or severe microvascular inflammation in the absence of glomerulonephritis</p>
          </list-item>
          <list-item>
            <p>Increased gene expression of gene transcripts strongly suggests antibody-mediated rejection</p>
          </list-item>
        </list>
        <p>3. Positive DSA antibodies to HLA and non-HLA antigens.</p>
        <p>II) CATMR is classified as follows (after ruling out other causes of IFTA):</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade IA:</bold> More than&#x000a0;25% interstitial inflammation of the cortex with &#x0201c;moderate tubulitis&#x0201d; in 1 or more tubules, excluding severely atrophic tubules.</p>
          </list-item>
          <list-item>
            <p><bold>Grade IB:</bold> Greater than&#x000a0;25% interstitial inflammation of the cortex with &#x0201c;severe tubulitis&#x0201d; in 1 or more tubules, excluding severely atrophic tubules</p>
          </list-item>
          <list-item>
            <p><bold>Grade II: </bold>Chronic allograft arteriopathy indicated by neointima formation, intimal arterial fibrosis, and mononuclear infiltration</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19539.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of CKTR remains challenging, mainly due to irreversibility at the time of diagnosis. Management, therefore, focuses on the prevention and early management of AR rather than treating CKTR. Adequacy of immunosuppression and patient adherence are pivotal for preventing AR, which later translates into a lower incidence of CKTR. Optimizing HLA matching reduces the chances of early allograft injury, further decreasing the risk of chronic allograft loss.<xref ref-type="bibr" rid="article-19539.r26">[26]</xref>&#x000a0;Moreover, early treatment of acute antibody-mediated rejection with intravenous immunoglobulin, plasmapheresis, or steroids will also reduce the risk of chronic allograft loss.<xref ref-type="bibr" rid="article-19539.r8">[8]</xref></p>
        <p>Most immunosuppressive regimens in the United States include a CNI, an antimetabolite, and corticosteroids. Although extremely effective, CNIs carry a high risk of chronic nephrotoxicity. Two methods that were suggested to balance efficacy and toxicity are (1) Guiding dosage by monitoring blood drug levels and (2) CNI sparing strategies. The four main approaches to minimize CNI exposure are CNI minimization, conversion, withdrawal, and avoidance.</p>
        <p><bold>CNI Minimization:</bold> Minimization refers to lowering target blood trough levels of CNIs, with or without another immunosuppressive agent. A systematic review and meta-analysis showed that CNI minimization was associated with a relatively low risk of AR and overall improved allograft function.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref>&#x000a0;The timing of CNI minimization was also studied. CNI minimization during the first six months post-transplant reduced the incidence of rejection compared to reducing CNI doses in the second 6 months post-transplant. No head to head trials, however, were conducted to compare early and late minimization directly.</p>
        <p>Combining low dose CNI with mycophenolic acid (MPA) preparations also reduced the risk of AR with no difference in mortality. Pairing CNI minimization with a mammalian target of rapamycin (mTOR) inhibitor (such as sirolimus or everolimus) did not increase the risk of biopsy-proven AR. It led to an improvement in kidney function in some studies. It is worth noting, however, that full dose CNI plus mTOR inhibitor therapy increases the risk of nephrotoxicity.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref></p>
        <p><bold>CNI&#x000a0;</bold><bold>Conversion:</bold> Conversion refers to switching CNI to another maintenance drug. Converting from CNI to an mTOR inhibitor showed improvement in kidney function, which was more observed with the conversion from cyclosporine compared to tacrolimus.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref>&#x000a0;Conversion to an mTOR inhibitor was also associated with a lower risk of cytomegalovirus (CMV) infection.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref>&#x000a0;Conversion to sirolimus showed better outcomes in patients with GFR exceeding 40 ml/min with less proteinuria, suggesting that conversion should occur before significant parenchymal damage.<xref ref-type="bibr" rid="article-19539.r28">[28]</xref>&#x000a0;Grimbert et al. suggested that early conversion to mTOR inhibitors within one year was associated with increased production of dnDSA, which increased the risk of antibody-mediated rejection. Therefore, conversion to mTOR inhibitor therapy with the elimination of CNI therapy should be performed with great caution and may increase the risk of CKTR. Late conversion after one year was not associated with increased dsDNA.<xref ref-type="bibr" rid="article-19539.r29">[29]</xref>&#x000a0;Evidence from studies of conversion to azathioprine, mycophenolate sodium, and belatacept was insufficient to draw conclusions.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref></p>
        <p><bold>CNI&#x000a0;</bold><bold>Withdrawal:</bold> Withdrawal refers to tapering CNIs until completely discontinued. CNI withdrawal with either MPA or mTOR inhibitor-based regimens was associated with an increased risk of rejection. Early withdrawal (&#x0003c;6 months post-transplant) was associated with an increased risk of graft loss, with insufficient evidence for both rejection and a decrease in renal function. Late withdrawal with the continuation of MPA preparations was associated with an overall greater risk of rejection.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref>&#x000a0;CNI withdrawal from azathioprine-based regimens was also associated with increased rejection.<xref ref-type="bibr" rid="article-19539.r28">[28]</xref></p>
        <p><bold>CNI&#x000a0;</bold><bold>Avoidance:</bold> Avoidance refers to CNI free regimens planned from the start. Initial trials to avoid CNIs while using daclizumab or anti-thymocyte globulin were associated with an increased risk of AR, which required reintroduction of CNIs in some patients.<xref ref-type="bibr" rid="article-19539.r28">[28]</xref>&#x000a0;Sirolimus-based immunosuppression regimens were also compared to CNI based regimens. Comparing sirolimus to tacrolimus in MPA-based regimens showed an increased risk of graft loss. Sirolimus, however, was associated with improved kidney function and reduced risk of CMV infection.<xref ref-type="bibr" rid="article-19539.r27">[27]</xref></p>
        <p>Belatacept, a novel fusion protein that inhibits T cell activation, was also compared to CNI based regimens. Vincenti et al. randomized patients into three groups; a cyclosporine, an intensive belatacept, and a less intensive belatacept-based regimen. Patients were followed for seven years. Patients on belatacept-based regimens showed a 43% reduction in risk of graft loss and death, compared to cyclosporine. Kidney function improved in both belatacept-based regimens, while it declined with cyclosporine.<xref ref-type="bibr" rid="article-19539.r30">[30]</xref>&#x000a0;</p>
        <p>Non-immunological management of CKTR includes tight control of blood pressure and lipid levels.<xref ref-type="bibr" rid="article-19539.r10">[10]</xref>&#x000a0;The KDIGO recommends maintaining blood pressure of over 130/80 in kidney transplant recipients.<xref ref-type="bibr" rid="article-19539.r20">[20]</xref>&#x000a0;Hyperlipidemia control with HMG-CoA reductase inhibitors also improves patient survival in kidney transplant recipients.<xref ref-type="bibr" rid="article-19539.r31">[31]</xref>&#x000a0;The data regarding the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is contradicting, with a possible benefit in patients with chronic allograft dysfunction and proteinuria.<xref ref-type="bibr" rid="article-19539.r32">[32]</xref><xref ref-type="bibr" rid="article-19539.r33">[33]</xref><xref ref-type="bibr" rid="article-19539.r34">[34]</xref><xref ref-type="bibr" rid="article-19539.r35">[35]</xref>&#x000a0;ACE inhibitors and ARBs should be used cautiously with CNIs due to an increased risk of hyperkalemia and azotemia. Some authors suggest a possible role for vitamin D in increasing graft survival; however, prospective studies are required to confirm efficacy.<xref ref-type="bibr" rid="article-19539.r11">[11]</xref></p>
      </sec>
      <sec id="article-19539.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>CKTR requires differentiation from other causes of late kidney allograft dysfunction:</p>
        <p>
<bold>Calcineurin Inhibitor (CNI) Toxicity </bold>
</p>
        <p>CNIs are among the most widely used immunosuppressive medications in kidney transplantation. The introduction of cyclosporine and tacrolimus in the early 1980s and late 1990s, respectively, lead to improved clinical outcomes.<xref ref-type="bibr" rid="article-19539.r28">[28]</xref>&#x000a0;Acute CNI toxicity is associated with hypertension, thrombotic microangiopathy, and kidney dysfunction secondary to afferent arteriolar vasoconstriction and up-regulation of fibrotic cytokines such as TGF-beta. CNIs also increase the risk of hypertension, post-transplant type 2 diabetes, and hyperlipidemia, all of which are risk factors for late kidney allograft loss. Histologically, chronic CNI toxicity presents with IFTA, similar to what may present as a consequence of CKTR. Therefore it is imperative to differentiate CKTR from CNI toxicity on biopsy. Histologically, CNI toxicity characteristically demonstrates striped interstitial fibrosis, medial arteriolar hyalinosis, tubular microcalcification, vacuolization, and atrophy. The presence of TG, peritubular capillary inflammation, and C4d deposition are all more specific for CKTR.<xref ref-type="bibr" rid="article-19539.r28">[28]</xref></p>
        <p>
<bold>BK-Virus Associated Nephropathy (BKVAN)</bold>
</p>
        <p>BKVAN is also a significant cause of late allograft dysfunction and requires differentiation from CKTR. BKVAN occurs when the BK virus, a polyomavirus, propagates in the face of immunosuppression. Most transplant centers screen for BK virus in the bloodstream during the first year post-transplant, and particularly high-level viremia tends to correlate with BKVAN. Histologically, BKVAN can present with tubulointerstitial scarring similar to CKTR. Suspicious biopsy findings need confirmation by polymerase chain reaction (PCR) detection of viral DNA in the blood, characteristic intranuclear viral particles on electron microscopy, and/or BK virus detection using immunohistochemistry and in situ hybridization (e.g., staining for the SV40 large T antigen).<xref ref-type="bibr" rid="article-19539.r3">[3]</xref></p>
        <p>
<bold>Recurrent or De-Novo Glomerular Disease</bold>
</p>
        <p>Recurrent glomerulonephritis (GN) causes approximately 8.4% of late renal allograft loss.<xref ref-type="bibr" rid="article-19539.r3">[3]</xref>&#x000a0;Dense deposit disease and focal segmental glomerulonephritis (FSGS) are associated with a high risk of recurrence after transplantation, with a poor prognosis.<xref ref-type="bibr" rid="article-19539.r3">[3]</xref>&#x000a0;Differentiating GN from CKTR can be done by history, laboratory, and histopathology testing. A history of GN pre-transplantation with similar findings on urinary sediment post-transplantation supports a recurrence of GN, particularly if nephrotic range proteinuria is present, while DSA positivity supports CKTR. Histologically, both can be differentiated by light microscopy, electron microscopy, and immunofluorescence.</p>
      </sec>
      <sec id="article-19539.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of CKTR and late allograft loss depends on the degree of fibrosis and reversibility of rejection at the time of diagnosis. Denisov et al. suggested that measuring hemoglobin, creatinine, and proteinuria 1-year post-transplant can be beneficial in the prognostication of kidney transplantation.<xref ref-type="bibr" rid="article-19539.r36">[36]</xref>&#x000a0;Indeed, a calculator for prognostication was patented and is available on the internet in Russian with a reported 92% accuracy for the prediction of renal graft function three years post-transplant.<xref ref-type="bibr" rid="article-19539.r36">[36]</xref>&#x000a0;Further studies are needed, however, to confirm its accuracy.</p>
      </sec>
      <sec id="article-19539.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The main complication of CKTR is allograft loss, which leads to kidney failure and possibly death, especially in patients who are poor candidates for repeat kidney transplantation. Patient complications include anxiety and depression, with an increased risk of mortality and worse quality of life with dialysis re-initiation. Kaplan et al. reported a less than 40% chance of at least 10-year survival in patients with kidney allograft failure.<xref ref-type="bibr" rid="article-19539.r37">[37]</xref>&#x000a0;Cardiovascular disease is the most common cause of death, followed by infection, which is mainly due to prior exposure to immunosuppression medications.<xref ref-type="bibr" rid="article-19539.r38">[38]</xref>&#x000a0;The economic burden of rejection and dialysis re-initiation is also detrimental for both the patient and the community.<xref ref-type="bibr" rid="article-19539.r1">[1]</xref></p>
      </sec>
      <sec id="article-19539.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Renal transplant recipients require counseling and education regarding each of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>The importance of medication adherence in maintaining a healthy allograft and prolonging its viability</p>
          </list-item>
          <list-item>
            <p>The importance of regular follow up with their transplant nephrologist</p>
          </list-item>
          <list-item>
            <p>The risk factors and causes of chronic kidney transplant rejection</p>
          </list-item>
          <list-item>
            <p>The signs and symptoms of chronic kidney transplant rejection</p>
          </list-item>
          <list-item>
            <p>The complications and consequences of chronic kidney transplant rejection</p>
          </list-item>
          <list-item>
            <p>The available treatment options for&#x000a0;chronic kidney transplant rejection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19539.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Chronic kidney transplant rejection poses a risk of allograft loss, increasing patient morbidity, and mortality. Acute rejection is a significant risk factor for chronic rejection. Thus, an interprofessional team approach to diagnosis and management is crucial.</p>
        <p>Evaluation starts with a thorough history taking and ordering the necessary lab tests ordered by the specialist/clinician. Immunosuppression medication levels need regular monitoring; this should include the services of a board-certified pharmacotherapy pharmacist. The pharmacist can also verify dosing and perform medication reconciliation. Renal ultrasonography is an inexpensive and non-invasive tool that can aid diagnosis. A biopsy is often necessary&#x000a0;for definitive diagnosis and ruling out other causes of allograft injury. The management of&#x000a0;chronic kidney transplant rejection&#x000a0;remains challenging, mainly due to irreversibility at the time of diagnosis. Management, therefore, focuses on the prevention and early management of acute rejection rather than treating chronic rejection. Patient adherence to immunosuppressive medications is essential in preventing acute rejection and late allograft loss; nursing staff is critical to following and assessing patient compliance. Improving health care professionals' knowledge of how to promptly evaluate and treat this condition will help improve patient outcomes. Early and effective communication between the patient, primary care clinician, pharmacist, and transplant nephrologist is crucial for early diagnosis and treatment to prevent allograft loss. Transplantation nurses monitor patients, provide education, and document these for the team. These interprofessional case dynamics are vital to achieving optimal outcomes for patients with CKTR. [Level 5]</p>
      </sec>
      <sec id="article-19539.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19539&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19539">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/chronic-kidney-transplant-rejection-ongoing-rejection-of-a-transplanted-kidney/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19539">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19539/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19539">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19539.s16">
        <title>References</title>
        <ref id="article-19539.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muduma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Odeyemi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Smith-Palmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.</article-title>
            <source>Adv Ther</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>345</fpage>
            <page-range>345-56</page-range>
            <pub-id pub-id-type="pmid">26905265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sellar&#x000e9;s</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Freitas</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reeve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Einecke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hidalgo</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Famulski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.</article-title>
            <source>Am J Transplant</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>388</fpage>
            <page-range>388-99</page-range>
            <pub-id pub-id-type="pmid">22081892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nankivell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Chronic allograft nephropathy: current concepts and future directions.</article-title>
            <source>Transplantation</source>
            <year>2006</year>
            <month>Mar</month>
            <day>15</day>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>643</fpage>
            <page-range>643-54</page-range>
            <pub-id pub-id-type="pmid">16534463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Becker</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Morath</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Suesal</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Immune mechanisms of acute and chronic rejection.</article-title>
            <source>Clin Biochem</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>49</volume>
            <issue>4-5</issue>
            <fpage>320</fpage>
            <page-range>320-3</page-range>
            <pub-id pub-id-type="pmid">26851348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Racusen</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Birk</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cascalho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Demetris</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Drachenberg</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lerut</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liapis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mannon</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mihatsch</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Nankivell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Nickeleit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Papadimitriou</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Platt</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Salinas-Madriga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Seron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sheaff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weening</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').</article-title>
            <source>Am J Transplant</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>518</fpage>
            <page-range>518-26</page-range>
            <pub-id pub-id-type="pmid">17352710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loupy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lefaucheur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roufosse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Glotz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nankivell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Akalin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alachkar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bagnasco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bouatou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Duong van Huyen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Mannon</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Naesens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nickeleit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nickerson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Segev</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Stegall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Racusen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Solez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.</article-title>
            <source>Am J Transplant</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-307</page-range>
            <pub-id pub-id-type="pmid">29243394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Current pathological perspectives on chronic rejection in renal allografts.</article-title>
            <source>Clin Exp Nephrol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>943</fpage>
            <page-range>943-951</page-range>
            <pub-id pub-id-type="pmid">27848058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Ters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Keddis</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Rodrigo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Stegall</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Kidney allograft survival after acute rejection, the value of follow-up biopsies.</article-title>
            <source>Am J Transplant</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>2334</fpage>
            <page-range>2334-41</page-range>
            <pub-id pub-id-type="pmid">23865852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenz</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Schinstock</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Groehler</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Verdick</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Stegall</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology.</article-title>
            <source>Transplant Direct</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>e392</fpage>
            <pub-id pub-id-type="pmid">30498769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bia</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Nonimmunologic causes of late renal graft loss.</article-title>
            <source>Kidney Int</source>
            <year>1995</year>
            <month>May</month>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>1470</fpage>
            <page-range>1470-80</page-range>
            <pub-id pub-id-type="pmid">7637276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Regalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alfieri</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Nutritional Vitamin D in Renal Transplant Patients: Speculations and Reality.</article-title>
            <source>Nutrients</source>
            <year>2017</year>
            <month>May</month>
            <day>27</day>
            <volume>9</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28554998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nankivell</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Borrows</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Natural history, risk factors, and impact of subclinical rejection in kidney transplantation.</article-title>
            <source>Transplantation</source>
            <year>2004</year>
            <month>Jul</month>
            <day>27</day>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>242</fpage>
            <page-range>242-9</page-range>
            <pub-id pub-id-type="pmid">15280685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaston</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cecka</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kasiske</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Fieberg</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Leduc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Gourishankar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mannon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rush</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.</article-title>
            <source>Transplantation</source>
            <year>2010</year>
            <month>Jul</month>
            <day>15</day>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>68</fpage>
            <page-range>68-74</page-range>
            <pub-id pub-id-type="pmid">20463643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stegall</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Gloor</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Textor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>The histology of solitary renal allografts at 1 and 5 years after transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>698</fpage>
            <page-range>698-707</page-range>
            <pub-id pub-id-type="pmid">21062418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halloran</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>T cell-mediated rejection of kidney transplants: a personal viewpoint.</article-title>
            <source>Am J Transplant</source>
            <year>2010</year>
            <month>May</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>1126</fpage>
            <page-range>1126-34</page-range>
            <pub-id pub-id-type="pmid">20346061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascual</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-S&#x000e1;ez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Chronic renal allograft injury: early detection, accurate diagnosis and management.</article-title>
            <source>Transplant Rev (Orlando)</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>280</fpage>
            <page-range>280-90</page-range>
            <pub-id pub-id-type="pmid">22902496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Nankivell</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Chronic renal allograft dysfunction.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>10</issue>
            <fpage>3015</fpage>
            <page-range>3015-26</page-range>
            <pub-id pub-id-type="pmid">16120819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stegall</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gaston</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cosio</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Through a glass darkly: seeking clarity in preventing late kidney transplant failure.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-9</page-range>
            <pub-id pub-id-type="pmid">25097209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marqu&#x000e9;s</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Goenaga</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Royo</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Escol&#x000e1;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Fern&#x000e1;ndez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Unanua</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Evolution of the renal function is a better predictor of long-term survival than serum creatinine.</article-title>
            <source>Transplant Proc</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>3701</fpage>
            <page-range>3701-4</page-range>
            <pub-id pub-id-type="pmid">16386511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group</collab>
            <article-title>KDIGO clinical practice guideline for the care of kidney transplant recipients.</article-title>
            <source>Am J Transplant</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>9 Suppl 3</volume>
            <fpage>S1</fpage>
            <page-range>S1-155</page-range>
            <pub-id pub-id-type="pmid">19845597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiebe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nickerson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation.</article-title>
            <source>Curr Opin Organ Transplant</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>470</fpage>
            <page-range>470-7</page-range>
            <pub-id pub-id-type="pmid">23695596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radermacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stuht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hiss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eisenberger</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luft</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Gwinner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The renal arterial resistance index and renal allograft survival.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Jul</month>
            <day>10</day>
            <volume>349</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-24</page-range>
            <pub-id pub-id-type="pmid">12853584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwenger</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Korosoglou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hinkel</surname>
                <given-names>UP</given-names>
              </name>
              <name>
                <surname>Morath</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sommerer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dikow</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hardt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000fc;cherer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katus</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Zeier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy.</article-title>
            <source>Am J Transplant</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>609</fpage>
            <page-range>609-15</page-range>
            <pub-id pub-id-type="pmid">16468973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Racusen</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Solez</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Glotz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>David-Neto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bagnasco</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cendales</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Demetris</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Drachenberg</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Farver</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Farris</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liapis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loupy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nickeleit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Randhawa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Rush</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
              <collab>Banff meeting report writing committee</collab>
            </person-group>
            <article-title>Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.</article-title>
            <source>Am J Transplant</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>272</fpage>
            <page-range>272-83</page-range>
            <pub-id pub-id-type="pmid">24472190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hidalgo</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Sis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sellares</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Einecke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Halloran</surname>
                <given-names>PF</given-names>
              </name>
            </person-group>
            <article-title>NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection.</article-title>
            <source>Am J Transplant</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>1812</fpage>
            <page-range>1812-22</page-range>
            <pub-id pub-id-type="pmid">20659089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pascual</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Theruvath</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tolkoff-Rubin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cosimi</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Strategies to improve long-term outcomes after renal transplantation.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Feb</month>
            <day>21</day>
            <volume>346</volume>
            <issue>8</issue>
            <fpage>580</fpage>
            <page-range>580-90</page-range>
            <pub-id pub-id-type="pmid">11856798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawinski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trofe-Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Uhl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tuteja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaczmarek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Umscheid</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.</article-title>
            <source>Am J Transplant</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>2117</fpage>
            <page-range>2117-38</page-range>
            <pub-id pub-id-type="pmid">26990455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camilleri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bridson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Halawa</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.</article-title>
            <source>Exp Clin Transplant</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>471</fpage>
            <page-range>471-483</page-range>
            <pub-id pub-id-type="pmid">27213490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimbert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thaunat</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now?</article-title>
            <source>Transpl Int</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>7</issue>
            <fpage>647</fpage>
            <page-range>647-657</page-range>
            <pub-id pub-id-type="pmid">28445619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vincenti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rostaing</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grinyo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gaite</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moal</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mondragon-Ramirez</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Polinsky</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Meier-Kriesche</surname>
                <given-names>HU</given-names>
              </name>
              <name>
                <surname>Munier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Belatacept and Long-Term Outcomes in Kidney Transplantation.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Jan</month>
            <day>28</day>
            <volume>374</volume>
            <issue>4</issue>
            <fpage>333</fpage>
            <page-range>333-43</page-range>
            <pub-id pub-id-type="pmid">26816011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Statin use prolongs patient survival after renal transplantation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>2037</fpage>
            <page-range>2037-40</page-range>
            <pub-id pub-id-type="pmid">18842988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiremath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fergusson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doucette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mulay</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Knoll</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence.</article-title>
            <source>Am J Transplant</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>7</volume>
            <issue>10</issue>
            <fpage>2350</fpage>
            <page-range>2350-60</page-range>
            <pub-id pub-id-type="pmid">17845569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heinze</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mitterbauer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Regele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kramar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Winkelmayer</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Oberbauer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>889</fpage>
            <page-range>889-99</page-range>
            <pub-id pub-id-type="pmid">16481415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Opelz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zeier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morath</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hler</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>3257</fpage>
            <page-range>3257-62</page-range>
            <pub-id pub-id-type="pmid">17035607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibrahim</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Connaire</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Najafian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lentsch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ericksen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bodner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasiske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mauer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II blockade in kidney transplant recipients.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>320</fpage>
            <page-range>320-7</page-range>
            <pub-id pub-id-type="pmid">23308016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denisov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zakharov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ksenofontova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Onishchenko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Golubova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kichatyi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zakharova</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Clinical Course and Outcomes of Late Kidney Allograft Dysfunction.</article-title>
            <source>J Transplant</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>7401808</fpage>
            <pub-id pub-id-type="pmid">27478631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Meier-Kriesche</surname>
                <given-names>HU</given-names>
              </name>
            </person-group>
            <article-title>Death after graft loss: an important late study endpoint in kidney transplantation.</article-title>
            <source>Am J Transplant</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>10</issue>
            <fpage>970</fpage>
            <page-range>970-4</page-range>
            <pub-id pub-id-type="pmid">12482151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19539.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bunthof</surname>
                <given-names>KLW</given-names>
              </name>
              <name>
                <surname>Hazzan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hilbrands</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Review: Management of patients with kidney allograft failure.</article-title>
            <source>Transplant Rev (Orlando)</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>178</fpage>
            <page-range>178-186</page-range>
            <pub-id pub-id-type="pmid">29628415</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
